Epifanio Fichera

Epifanio Fichera

Auto-generated profile, based on publicly available information

Epifanio Fichera

Etna Biotech S.R.L, via Vincenzo Lancia, 57—Zona Industriale Blocco Palma 1, Catania, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
PCPedro Amado Cecilio
Pedro Amado Cecilio
BPBegoña Pérez-Cabezas
Begoña Pérez-Cabezas
LFLaura Fernández
Laura Fernández
JMJavier Moreno
Javier Moreno
Eugenia CarrilloEugenia Carrillo
Eugenia Carrillo
Anabela Cordeiro-Da-SilvaAnabela Cordeiro-Da-Silva
Anabela Cordeiro-Da-Silva
The notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine available for human leishmaniasis. We optimized and assessed in vivo the safety and immunogenicity of an innovative vaccine candidate against human visceral leishmaniasis (VL), consisting of Virus-Like Particles (VLP) loaded with three different recombinant proteins (LJL143 from Lutzomyia longipalpis saliva as the vector-derived (VD) component, and KMP11 and LeishF3+, as parasite-derived (PD) antigens) and adjuvanted with GLA-SE, a TLR4 agonist. No apparent adverse reactions were observed during the experimental time-frame, which together with the normal hematological parameters detected seems to point to the safety of the formulation. Furthermore, measurements of antigen-specific cellular and humoral responses, generally higher in immunized versus control groups, confirmed the immunogenicity of the vaccine formulation. Interestingly, the immune responses against the VD protein were reproducibly more robust than those elicited against leishmanial antigens, and were apparently not caused by immunodominance of the VD antigen. Remarkably, priming with the VD protein alone and boosting with the complete vaccine candidate contributed towards an increase of the immune responses to the PD antigens, assessed in the form of increased ex vivo CD4+ and CD8+ T cell proliferation against both the PD antigens and total Leishmania antigen (TLA). Overall, our immunogenicity data indicate that this innovative vaccine formulation represents a promising anti-Leishmania vaccine whose efficacy deserves to be tested in the context of the “natural infection”. Although vaccination is accepted as a potentially effective approach to prevent leishmaniasis, to date there is no vaccine available for human disease. The research on the topic is therefore extremely important, and the design and testing of new vaccine approaches, as well as non-traditional immunization schemes continues to be as relevant as before. This study proposes an innovative vaccine approach for human visceral leishmaniasis, not only due to its multi-antigen nature which contemplates both parasite and vector derived proteins, but also because it explores the possibility of the use of Influenza virosomes as antigen-delivery vehicles. A strong TLR-4 agonist completes the vaccine formulation. Here we show the rationale-behind this vaccine approach, the safety of all the vaccine components in our in vivo context, and immunogenicity studies of the optimized vaccine candidate in mice that explored the contribution of the virosome to the antigen-elicited immune responses. Additionally, we tested an unusual immunization scheme that potentiated the final vaccine-elicited immune responses. This prime-boost immunization approach gives relevance to the use of both parasite and vector derived antigens together as an anti-Leishmania vaccine, and proposes a new strategy for vaccination in endemic areas, where people are constantly exposed to sand fly bites.

9 May 2016 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
Francesco PapparlardoFrancesco Papparlardo
Francesco Papparlardo
EFEpifanio Fichera
Epifanio Fichera
NPNicoletta Paparone
Nicoletta Paparone
ALAlessandro Lombardo
Alessandro Lombardo
MPMarzio Pennisi
Marzio Pennisi
SMSanto Motta
Santo Motta
Motivation: Vaccines represent the most effective and cost-efficient weapons against a wide range of diseases. Nowadays new generation vaccines based on sub-unit antigens reduce adverse effects in high risk individuals. However, vaccine antigens are often poor immunogens when administered alone. Adjuvants represent a good strategy to overcome such hurdles, indeed they are able to: enhance the immune response; allow antigens sparing; accelerate the specific immune response; and increase vaccine efficacy in vulnerable groups such as newborns, elderly or immuno-compromised people. However, due to safety concerns and adverse reactions, there are only a few adjuvants approved for use in humans. Moreover, in practice current adjuvants sometimes fail to confer adequate stimulation. Hence, there is an imperative need to develop novel adjuvants that overcome the limitations of the currently available licensed adjuvants.

24 February 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RMRossana Mineo
Rossana Mineo
EFEpifanio Fichera
Epifanio Fichera
SLShu-Jian Liang
Shu-Jian Liang
YFYoko Fujita-Yamaguchi
Yoko Fujita-Yamaguchi

1 April 2000 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
PDF file
EFE. Fichera
E. Fichera
SLS. Liang
S. Liang
Zhao-dong XuZhao-dong Xu
Zhao-dong Xu
NGN. Guo
N. Guo
RMR. Mineo
R. Mineo
YFYoko Fujita-Yamaguchi
Yoko Fujita-Yamaguchi

1 January 2009
Verified
Book Chapter
Closed access
PDF file
EFEpifanio Fichera
Epifanio Fichera
DFDiana Felnerova
Diana Felnerova
RMRobert Mischler
Robert Mischler
JVJean-François Viret
Jean-François Viret
RGReinhard Glueck
Reinhard Glueck

1 July 2001
Verified
Closed access
SMS Molica
S Molica
Rita Carlotta SantoroRita Carlotta Santoro
Rita Carlotta Santoro
FIF Iuliano
F Iuliano
FRFrancesco Di Raimondo
Francesco Di Raimondo
EFE Fichera
E Fichera
RGR Giustolisi
R Giustolisi